Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Current literature regarding the effect of selenium supplementation on the risk of diabetes is inconclusive. Hence, a longitudinal study was conducted to investigate the effect of selenium supplementation on serum glucose levels in elderly men. Methods: Data were obtained from 699 men participating in a randomized double-blind placebo-controlled Phase 3 clinical trial investigating the effects of two doses of selenium (200 and 400μg/day) compared with placebo on the incidence of prostate cancer. Subjects were followed every 6 months for up to 5 years. Serum glucose levels were obtained every 6 months. Mixed-effects regression models were used to assess whether the rate of change of serum glucose levels was significantly different in the selenium-supplemented groups compared with placebo. Sensitivity analyses were performed to assess the robustness of findings and to minimize the possibility of residual bias due to fasting status. Results: Of the total 2893 glucose measurements, 734 were performed when the subject had been fasting for ≥8h. Changes in serum glucose levels during the course of the trial did not differ significantly between the placebo and selenium 200μg/day (P=0.98) and 400μg/day (P=0.81) groups. Sensitivity analyses demonstrated comparable results for models using the total population and models restricted to subjects with only fasting glucose data. Conclusion: These results do not support a relationship between selenium supplementation and risk of diabetes. Hence, recommendations regarding selenium supplementation based on increased risk of diabetes seem premature.

Original languageEnglish (US)
Pages (from-to)465-470
Number of pages6
JournalJournal of Diabetes
Volume5
Issue number4
DOIs
StatePublished - Dec 2013

Fingerprint

Selenium
Prostatic Neoplasms
Glucose
Serum
Placebos
Fasting
Phase III Clinical Trials
Controlled Clinical Trials
Longitudinal Studies
Incidence
Population

Keywords

  • Prostate cancer
  • Selenium supplementation
  • Serum glucose

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{86e7b68fcd924a17a95c4d7dacda7564,
title = "Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer",
abstract = "Background: Current literature regarding the effect of selenium supplementation on the risk of diabetes is inconclusive. Hence, a longitudinal study was conducted to investigate the effect of selenium supplementation on serum glucose levels in elderly men. Methods: Data were obtained from 699 men participating in a randomized double-blind placebo-controlled Phase 3 clinical trial investigating the effects of two doses of selenium (200 and 400μg/day) compared with placebo on the incidence of prostate cancer. Subjects were followed every 6 months for up to 5 years. Serum glucose levels were obtained every 6 months. Mixed-effects regression models were used to assess whether the rate of change of serum glucose levels was significantly different in the selenium-supplemented groups compared with placebo. Sensitivity analyses were performed to assess the robustness of findings and to minimize the possibility of residual bias due to fasting status. Results: Of the total 2893 glucose measurements, 734 were performed when the subject had been fasting for ≥8h. Changes in serum glucose levels during the course of the trial did not differ significantly between the placebo and selenium 200μg/day (P=0.98) and 400μg/day (P=0.81) groups. Sensitivity analyses demonstrated comparable results for models using the total population and models restricted to subjects with only fasting glucose data. Conclusion: These results do not support a relationship between selenium supplementation and risk of diabetes. Hence, recommendations regarding selenium supplementation based on increased risk of diabetes seem premature.",
keywords = "Prostate cancer, Selenium supplementation, Serum glucose",
author = "Algotar, {Amit Mohan} and Chiu-Hsieh Hsu and Singh, {Parminder -} and Stratton, {Steven P}",
year = "2013",
month = "12",
doi = "10.1111/1753-0407.12041",
language = "English (US)",
volume = "5",
pages = "465--470",
journal = "Journal of Diabetes",
issn = "1753-0393",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer

AU - Algotar, Amit Mohan

AU - Hsu, Chiu-Hsieh

AU - Singh, Parminder -

AU - Stratton, Steven P

PY - 2013/12

Y1 - 2013/12

N2 - Background: Current literature regarding the effect of selenium supplementation on the risk of diabetes is inconclusive. Hence, a longitudinal study was conducted to investigate the effect of selenium supplementation on serum glucose levels in elderly men. Methods: Data were obtained from 699 men participating in a randomized double-blind placebo-controlled Phase 3 clinical trial investigating the effects of two doses of selenium (200 and 400μg/day) compared with placebo on the incidence of prostate cancer. Subjects were followed every 6 months for up to 5 years. Serum glucose levels were obtained every 6 months. Mixed-effects regression models were used to assess whether the rate of change of serum glucose levels was significantly different in the selenium-supplemented groups compared with placebo. Sensitivity analyses were performed to assess the robustness of findings and to minimize the possibility of residual bias due to fasting status. Results: Of the total 2893 glucose measurements, 734 were performed when the subject had been fasting for ≥8h. Changes in serum glucose levels during the course of the trial did not differ significantly between the placebo and selenium 200μg/day (P=0.98) and 400μg/day (P=0.81) groups. Sensitivity analyses demonstrated comparable results for models using the total population and models restricted to subjects with only fasting glucose data. Conclusion: These results do not support a relationship between selenium supplementation and risk of diabetes. Hence, recommendations regarding selenium supplementation based on increased risk of diabetes seem premature.

AB - Background: Current literature regarding the effect of selenium supplementation on the risk of diabetes is inconclusive. Hence, a longitudinal study was conducted to investigate the effect of selenium supplementation on serum glucose levels in elderly men. Methods: Data were obtained from 699 men participating in a randomized double-blind placebo-controlled Phase 3 clinical trial investigating the effects of two doses of selenium (200 and 400μg/day) compared with placebo on the incidence of prostate cancer. Subjects were followed every 6 months for up to 5 years. Serum glucose levels were obtained every 6 months. Mixed-effects regression models were used to assess whether the rate of change of serum glucose levels was significantly different in the selenium-supplemented groups compared with placebo. Sensitivity analyses were performed to assess the robustness of findings and to minimize the possibility of residual bias due to fasting status. Results: Of the total 2893 glucose measurements, 734 were performed when the subject had been fasting for ≥8h. Changes in serum glucose levels during the course of the trial did not differ significantly between the placebo and selenium 200μg/day (P=0.98) and 400μg/day (P=0.81) groups. Sensitivity analyses demonstrated comparable results for models using the total population and models restricted to subjects with only fasting glucose data. Conclusion: These results do not support a relationship between selenium supplementation and risk of diabetes. Hence, recommendations regarding selenium supplementation based on increased risk of diabetes seem premature.

KW - Prostate cancer

KW - Selenium supplementation

KW - Serum glucose

UR - http://www.scopus.com/inward/record.url?scp=84887018564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887018564&partnerID=8YFLogxK

U2 - 10.1111/1753-0407.12041

DO - 10.1111/1753-0407.12041

M3 - Article

C2 - 23489776

AN - SCOPUS:84887018564

VL - 5

SP - 465

EP - 470

JO - Journal of Diabetes

JF - Journal of Diabetes

SN - 1753-0393

IS - 4

ER -